Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Abilify
Pharma
BMS wins FDA approval for new schizophrenia med Cobenfy
Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has borne fruit with the approval of a promising new schizophrenia drug.
Fraiser Kansteiner
Sep 26, 2024 7:38pm
Otsuka, Lundbeck start ad push for long-acting bipolar drug
Jun 4, 2024 10:45am
Astellas, J&J, Sun and more—Fierce Pharma Asia
May 5, 2023 8:55am
FDA approves Teva, MedinCell's long-acting schizophrenia therapy
May 1, 2023 9:30am
FDA signs off on Otsuka and Lundbeck's longer-acting Abilify
Apr 28, 2023 11:00am
J&J scores FDA nod for twice-yearly schizophrenia treatment
Sep 1, 2021 8:00am
